Acrivon Therapeutics Inc(ACRV) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 5:27 PM ET (Korea 10/31 06:27)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -1.89 | Insider Own | 22.47% | Shs Outstand | 42.9M | Perf Week | -4.05% |
| Market Cap | 0.07B | Forward P/E | - | EPS next Y | 10.5% | Insider Trans | -0.2% | Shs Float | 33.2M | Perf Month | -17.41% |
| Enterprise Value | -0.02B | PEG | - | EPS next Q | -0.44 | Inst Own | 45.37% | Short Float | 5.23% | Perf Quarter | 6.41% |
| Income | -0.07B | P/S | - | EPS this Y | 8.42% | Inst Trans | 3.2% | Short Ratio | 5.75 | Perf Half Y | -20.57% |
| Sales | 0.00B | P/B | 0.82 | EPS next 5Y | 14.02% | ROA | -57.61% | Short Interest | 1.74M | Perf YTD | -31.12% |
| Book/sh | 2.02 | P/C | 0.79 | EPS past 3/5Y | -12.47% -51.39% | ROE | -64.63% | 52W High | -53.37% ($3.56) | Perf Year | -14.43% |
| Cash/sh | 2.1 | P/FCF | - | Sales past 3/5Y | - | ROIC | -84.69% | 52W Low | 30.71% ($1.27) | Perf 3Y | -68.02% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 16.04% | Gross Margin | - | Volatility(W/M) | 7.09% 6.54% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.12 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 7.99 | EPS Q/Q | 21.4% | Profit Margin | - | RSI (14) | 38.83 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 7.99 | Sales Q/Q | - | SMA20 | -7.11% ($1.79) | Beta | 1.94 | Target Price | $11.5 |
| Payout | - | Debt/Eq | 0.02 | Earnings | 2026/8/12 | SMA50 | -14.36% ($1.94) | Rel Volume | 0.55 | Prev Close | $1.76 |
| Employees | 76 | LT Debt/Eq | 0.01 | EPS/Sales Surpr. | 14.38% - | SMA200 | -6.11% ($1.77) | Avg Volume(3M) | 0.30M | Price | $1.66 |
| IPO | 2022/11/15 | Option/Short | No/Yes | Trades | 483 | Volume | 165,749 | Change | -5.68% |
🧬 This is a clinical-stage biotech company developing novel oncology drugs using a proteomics-based patient selection platform. Headquartered in the US, the company employs a strategy of pre-identifying patient populations whose tumors are most likely to respond to specific drugs, advancing its precision oncology pipeline.
Over the past 1 year, on the lower side
53% below its 1-year high.
Traded less than usual. That is 55% of its average volume.
ACRV has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +8.4% this year.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Long-term returns are roughly flat
Bought 3 years ago, your return today would be -68.0%.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 45.4%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #384 of 597 in the industry
Based on market cap of $71M.
CING#383 Cingulate Inc $72M PER - ACRV#384 Acrivon Therapeutics Inc $71M PER - 
CRDF#385 Cardiff Oncology Inc $69M PER - 
NMRA#386 Neumora Therapeutics Inc $69M PER - 
MNOV#387 Medicinova Inc $69M PER - 
FAQ
What kind of company is ACRV?
ACRV belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of ACRV?
The market cap of ACRV is approximately $71M, ranking 4,675 within its sector.
What is the 52-week high and low for ACRV?
ACRV has recorded a 52-week high of $3.56 and a low of $1.27.
